Barclays PLC Has $3.56 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Barclays PLC increased its stake in Structure Therapeutics Inc. (NASDAQ:GPCR) by 64.5% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 81,138 shares of the company’s stock after purchasing an additional 31,815 shares during the quarter. Barclays PLC’s holdings in Structure Therapeutics were worth $3,562,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in GPCR. Principal Financial Group Inc. acquired a new stake in Structure Therapeutics in the second quarter valued at $6,489,000. Natixis Advisors LLC lifted its stake in Structure Therapeutics by 29.4% in the 2nd quarter. Natixis Advisors LLC now owns 19,005 shares of the company’s stock valued at $746,000 after purchasing an additional 4,321 shares during the last quarter. Gilbert & Cook Inc. acquired a new stake in Structure Therapeutics in the 2nd quarter valued at about $229,000. TD Asset Management Inc grew its holdings in Structure Therapeutics by 47.9% during the second quarter. TD Asset Management Inc now owns 211,590 shares of the company’s stock worth $8,309,000 after purchasing an additional 68,490 shares during the period. Finally, Pier Capital LLC increased its position in Structure Therapeutics by 3.7% during the second quarter. Pier Capital LLC now owns 101,204 shares of the company’s stock worth $3,974,000 after buying an additional 3,647 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on GPCR shares. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Morgan Stanley assumed coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Finally, HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $86.50.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR opened at $27.90 on Monday. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -37.70 and a beta of -3.41. The stock’s fifty day moving average price is $35.32 and its two-hundred day moving average price is $38.63. Structure Therapeutics Inc. has a one year low of $26.23 and a one year high of $62.74.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.